Pane wikiwiki
Examine why $8.9B in AI drug discovery hasn't produced an approved solo-AI drug, and how custom peptide synthesis and analytics de-risk AI leads.
$8.9B Hoʻolilo ʻia, Aohe Laau Laau Solo-AI: He aha ka manaʻo no ka Peptide Chemistry
Ua kākau ʻia e Dr. ʻO Alexander Vance, PhD (Kemimi Peptide Lead & R&D Lunahooponopono) | Nānā ʻia no ka Pono ʻepekema e ka MOL Changes R&D Panel
Ma waena 2024 a 2026, ʻO ke kapikala ʻoihana a me nā pilikua biopharma i kau ʻia ma luna $8.9 piliona i loko o nā kahua ʻike lāʻau i alakaʻi ʻia e AI, ke koi ʻana i ke kālā ʻoihana makahiki ma ka ʻāpana i kahi kokoke $11 piliona ma mua o 340 ʻaelike. Nā hiʻohiʻona hoʻopulapula generative, nā hale hana transformer e like me ESM-2, a me nā mea hana wānana e like me AlphaFold3 ua hoʻololi i ka computational front-end o ka ʻike. Hiki i nā pipeline in-silico ke hoʻopuka i nā miliona o nā kaʻina peptide de novo a wānana i nā pilina paʻa paʻa i nā hola ma mua o nā mahina..
Akā naʻe, ʻoiai ʻo kēia hoʻokomo kālā ʻole i loaʻa ma mua, he ʻāina hoʻoponopono koʻikoʻi i koe: e like me ka 2026, ua loaʻa i ka lāʻau lapaʻau i hoʻokumu ʻia ʻo AI i ka ʻae piha FDA.
ʻOiai ʻoi aku ka maikaʻi o nā algorithms AI ma ke kaʻina hana a me ka nānā ʻana i nā moho mua, ʻAʻole loaʻa nā lāʻau lapaʻau kino ma kahi helu helu. Pono lākou e ola i ka ʻoiaʻiʻo maoli o ka synthesis solid-phase, nā palena hoʻoheheʻe wai, proteolysis enzymatic, a me ka lawe ʻana i ka ʻiʻo. No nā hui noiʻi peptide holomua, keia $8.9 ʻO ka ʻokoʻa piliona e lawe i kahi ʻōlelo maopopo: Hoʻoikaika ʻo AI i ka manaʻo kaʻina, akā pili pono ka hoʻomohala ʻana i ka peptide i ka synthesis bespoke, hoʻololi kemika i manaʻo ʻia, a me ka hōʻike ʻana i ke ʻano loiloi ikaika.
ʻO ka $8.9 Billion Disparity: Kiʻekiʻe Phase I Hits vs. Māhele II Attrition
No ka hoʻomaopopo ʻana i ke kumu ʻaʻole i hala nā kumu hoʻohālikelike i ka laina hoʻopau hoʻoponopono, Pono nā hui ʻike e nānā i kahi e kūleʻa ai ʻo AI—a ma kahi e pā ai i ka pā.
Wahi a a 2026 ka nānā ʻana o ka pipeline clinical o nā molekele i hoʻolālā ʻia e AI, ma mua o 173 Ua komo nā waiwai lāʻau lapaʻau i hoʻolālā ʻia e AI a i ʻole AI i nā hoʻokolohua lapaʻau kanaka ikaika ma ka honua holoʻokoʻa. Ma nā loiloi palekana mua, Hōʻike nā moho kamaʻāina AI i nā helu kūleʻa Phase I ma waena 80% a 90%, ʻaneʻane pāpālua ʻia nā awelika ʻoihana mōʻaukala o ka ʻaneʻane 50%. ʻOi aku ka maikaʻi o nā hiʻohiʻona generative i ka hoʻopaʻa ʻana i nā mea ʻawaʻawa paʻa, ka pale ʻana i nā manaʻo hoʻihoʻi, a me ka hoʻopololei ʻana i ke kūpono o ka ili paʻa paʻa.
In-Silico Ideation (Miliona o na Kaina)
Mākaʻikaʻi Mākaʻikaʻi (80–90% ka helu o ka holomua) ► Kiʻekiʻe In-Silico Target Fit Phase II Efficacy & ADME (~ 40% ka nui o ka holomua) ► ʻO ka Pā ʻAha Kino
Eia naʻe, i ka manawa e neʻe ai nā moho i ka Phase II efficacy a me nā hoʻokolohua pharmacokinetic, e hāʻule ka helu kūleʻa i nā awelika ʻoihana mōʻaukala ma kahi o 40%. ʻO nā ʻano hāʻule ʻole i ka Phase II ʻaʻole pinepine ʻia e ka hoʻopaʻa ʻana i nā āpau pili. aka, mai ka palaho pharmacokinetic i kuhi ʻole ʻia, maikaʻi ʻole ka hāʻawi ʻana i ka ʻiʻo, hoʻopalekana metabolic, a me ka hōʻiliʻili ʻana ma waho o ka pahuhopu.
E like me ka mea i hōʻike ʻia i kēia manawa biopharma VC hoʻokomo kālā, Ke hoʻomau nei nā mākeke kapikala i ka nānā ʻana i nā kahua "AI maʻemaʻe".. Hoʻohana ʻia nā hiʻohiʻona in-silico ma nā hana helu ikehu a me nā hoʻonohonoho hoʻomaʻamaʻa static. ʻAʻole hiki iā lākou ke wānana i ke ʻano o ke kaulahao peptide kino i ka wā o ka hoʻopili resin kiʻekiʻe, pehea ia e pili ai iā ia iho i ka serum, a i ʻole ka hoʻololi ʻana o kāna ʻaoʻao counterion i nā kaila ion membrane cell i nā mea ola.
No ke aha e hina ai nā ʻōkuhi AI Generative i ka Wet Lab
Ke hoʻololi nei nā kaʻina peptide de novo mai nā wānana algorithmic i ka synthesis kino, ʻike pinepine nā mea lāʻau lapaʻau i nā alaloa kino a me ka biophysical koʻikoʻi. Hoʻolālā nā algorithms generative i ka manawa kaʻina no ka hoʻopaʻa ʻana i ka ikehu a i ʻole ka hoʻokō ʻana i ka ʻili o ka ʻili me ka ʻole o ka ʻike maoli ʻana i ka hiki ke hoʻohana ʻia a i ʻole ka hoʻonā kino..
| ʻAno hāʻule | In-Silico Root Kumu | Hōʻike ʻia ʻo Wet-Lab kino |
|---|---|---|
| SPPS On-Resin Aggregation | Hydrophobic nui loa, lālā beta, a i ʻole ka nui o ka waika amino ʻala | ʻO ka hoʻokumu ʻana i ka pepa beta ma waena o nā kaulahao; hoʻopau ʻole ʻia ʻo Fmoc; ʻoki ʻia nā mea haumia holoi |
| Hoʻoheheʻe wai | Ka hāʻawi ʻana i ka hoʻopiʻi kaulike ʻole a me ka ʻāpana ili ʻole polar kiʻekiʻe | ʻO ka peptide gelling, ka ua, a i ʻole ka hoʻokuʻu ʻia ʻana o ke ao i nā bioassays |
| ʻO Proteolysis wikiwiki | Nā iwi kuamoʻo maʻalahi e hōʻike ana i nā paʻa peptide maoli | Serum hapalua ola < 15 mau minuke ma muli o ka degradation endo/exopeptidase |
| Counterion Cytotoxicity | Ka mālama ʻole ʻana i nā hopena counterion TFA i ka wā cleavage | Heluhelu ʻia nā mea ʻawaʻawa hoʻopunipuni a hoʻololi i ka pH assay |
1. Hoʻohui ʻia ʻo On-Resin i ka wā Solid-Phase Peptide Synthesis (SPSS)
Hoʻohui pinepine nā kumu hoʻohālike AI i nā kaʻina waiwai i nā koena hydrophobic (ʻO Val, Me, Leu, Ua haʻi aku ʻo Phe, Trp) e hoʻomāhuahua i ka pilina pili honua. I ka wā SPPS automated, i ka hiki ʻana o ke kaulahao peptide 8 i 15 koena ma ke kākoʻo paʻa, Hoʻohana kēia mau ʻāpana hydrophobic i nā hale beta-sheet inter-chain lōʻihi.
Nā noiʻi hou i paʻi ʻia ma Nature Chemistry ma ka nā hana o ka SPPS on-resin aggregation hōʻoia ʻo ka hoʻohui ʻana ma ka resin e kaupalena i ke komo ʻana o ka solvent a hoʻopaʻa i ka piperidine deprotection reagents. ʻO kēia ka hopena i ka wehe ʻole ʻana o Fmoc a me nā kaʻina holoi ʻoki ʻia (e.g., des-Val a i ʻole des-Leu haumia) e kaʻana like ana i nā waiwai chromatographic kokoke like me ka peptide, ʻaneʻane hiki ʻole ke hoʻokaʻawale ʻia ka maʻemaʻe kiʻekiʻe.
2. ʻO ka wai ʻole a me ka hui pū ʻana o ka wai
ʻOiai ke hoʻohui maikaʻi ʻia kahi kaʻina paʻakikī, ʻAʻole pinepine nā peptides linear de novo i ka mālama wai. ʻO ka maʻiʻo hydrophobic kiʻekiʻe e alakaʻi i ka pilina pilikino i nā pale physiological, ke kumu o ka peptide gelling, ʻōpua, a i ʻole ka ua hikiwawe i ka hana ʻana i nā koina bioassay (1–10 µM).
3. Hoʻohaʻahaʻa proteolytic wikiwiki
ʻO nā peptides laina i hoʻololi ʻole ʻia i haku wale ʻia me nā ʻakika L-amino maoli i loaʻa i nā iwi kuamoʻo maʻalahi me nā kaula amide i ʻike piha ʻia.. I ka serum a i ʻole ka moʻomeheu pūnaewele, hōʻike ʻia nā protease ma nā wahi a pau (e like me trypsin, chymotrypsin, a me nā carboxypeptidase) e hoʻokaʻawale i kēia mau hana laina i loko o nā minuke, ka hāʻawi ʻana i nā helu hoʻopaʻa paʻa in-silico i pili ʻole in-vitro a me in-vivo.
4. Trifluoroacetate (TFA) Kūʻē Kūʻē
Hoʻohana nā kaʻina hana cleavage maʻamau i ka wā SPPS i ka waikawa trifluoroacetic, e waiho ana i nā peptides hope loa e like me nā paʻakai TFA. ʻO ke koena TFA counterions e like me ka potent metabolic toxins i nā cell assays, hoʻololi i ka pH cellular a me ka hiki ke membrane. Me ka ʻole o ka hoʻololi counterion systematic, Hiki i nā mea noiʻi ke hoʻopaʻa i ka cytotoxicity maikaʻi ʻole a i ʻole ke kuhi hewa ʻana i nā mea hana hoʻāʻo e like me ka maikaʻi hui..
Ki Takeaway: He mea ʻole ka helu helu hoʻopaʻa helu kiʻekiʻe inā hoʻohui ka peptide kino i ka resin, precipitates in buffer, a hoʻohaʻahaʻa paha i ka serum i loko 15 minuke. Pono e hoʻomaka ka wet-lab de-risking ma ka pae hoʻolālā kaʻina.
ʻO ka Hui Hana Hana: Ke hoʻāʻo nei i nā kaʻina AI ma o ka Synthesis High-Throughput
E hoʻopaʻa i ka ʻokoʻa ma waena o ka manaʻo computational a me ka ʻoiaʻiʻo lapaʻau, Ke haʻalele nei nā hui biopharma alakaʻi i ke koho ma-silico maʻemaʻe no ka a Hana Hana Kemika AI-Peptide Hybrid. Ma keia kükohu, Hoʻokomo ʻia nā hale waihona puke i hana ʻia e AI me ka hoʻohana ʻana i ka synthesis kiʻekiʻe-throughput a me ka de-risking structural..
KAHIKI 1: HANAHANA IN-SILICO & HUI PRE-FILTERING Generative Diffusion / Hoʻohālike ESM-2 -> Ka wānana ʻana & Hōʻuluʻulu helu STAGE 2: HIGH-THROUGHPUT BESPOKE SYNTHESIS & KA HOOLOLI ANA I KA HANA KIEKIE SPPS -> Pseudoproline Dipeptides -> Kaʻikala / Stapling STAGE 3: ORTHOGONAL ANALYTICAL CHARACTERIZATION & DE-PILI RP-HPLC (Rs ≥ 1.5) -> ESI-MS kiʻekiʻe -> TFA Exchange -> Srility QC
Ka lanakila ʻana i nā "Sequences Paʻakikī" ma Synthesis
Ke hoʻomaka ka wānana kaʻina AI i nā helu hōʻuluʻulu kiʻekiʻe, Hoʻohana nā ʻenekini synthesis maʻamau i nā hana kemika kūikawā ma mua o ka hoʻolei ʻana i ke kaʻina:
- Pseudoproline Dipeptides: Hoʻokomo i ka Fmoc-oxazolidine dipeptides (e.g., Fmoc-Ser/Thr/Cys-oxazolidines) i nā wā hoʻolālā e hoʻopau i ka hoʻopaʻa ʻana o ka hydrogen iwi kuamoʻo beta i ka wā e hoʻolōʻihi ʻia ai ke kaulahao, ke pale ʻana i ka hoʻohui ʻana ma ka resin. I loko o nā benchmarks wet-lab me kahi 32-mer AI-designed hydrophobic target, ʻO ka hoʻokomo ʻana o ka pseudoproline dipeptides i hoʻonui ʻia i ka hoʻohui ʻana i ka hua mai 12% i 88%.
- Hoʻolālā Hoʻopalekana iwi kuamoʻo: Ke hoʻohana nei iā Hmb (2-hydroxy-4-methoxybenzyl) a i ʻole nā pale Dmb no ka manawa pōkole e hoʻopaʻa i ka amide hydrogen.
- ʻO Chaotropic Solvent Additives & Kiekie ka Mahana: ʻO ka hoʻohui ʻana i nā mea hoʻohui e like me LiCl i DMF a i ʻole ka hana ʻana i ka synthesis ma lalo o ka microwave / kahe kahe e mālama ʻia ai ka pehu resin a hōʻoia i nā kinetics hui piha..
Ma ka hoʻohui ʻana i nā mea kūikawā nā lawelawe hana peptide synthesis maʻamau, Hiki i nā hui noiʻi ke hōʻoia i nā moho paʻakikī i hana ʻia e AI ma ka pānaʻi milligram ma mua o ka hana ʻana i ke kapikala e alakaʻi i ka optimization.
Hoʻololi i manaʻo ʻia: Ke hoʻololi ʻana i nā Hits In-Silico i mau alakaʻi i mākaukau no ka Lab
Aneane hoʻopuka wale ʻo Raw AI i nā kaulahao laina o nā waikawa L-amino maoli. No ka hoʻololi ʻana i kēia mau hits mua i paʻa, koho, a me nā moho alakaʻi bioavailable, Hoʻohana nā mea lapaʻau lapaʻau i nā hoʻololi kemika i manaʻo ʻia e hāʻawi i ka mana conformational a me ka pale ʻana i ka metabolic.
Linear Unmodified AI Peptide Targeted Chemical Hoʻololi
• Ka Iwi Kū'ē Loa • Po'o-a-Huo / Laka Stapled • Hoʻokaʻawale Protease Hōʻike ʻia ► • Paʻi Kūʻē Kūʻē Protease • Hoʻuluʻulu Pepa-Peta Kiʻekiʻe • Hoʻonui ʻia ka Permeability Cell
1. Nā Laka Conformational: Cyclization a me Hydrocarbon Stapling
ʻO ka cyclization o ke poʻo a ka huelo a i ʻole ka ʻaoʻao-chain-to-side-chain lactam bridging e hoʻopaʻa i ka peptide i loko o kona ʻano hana biologically.. Hāʻawi kēia rigidification i ʻelua mau pōmaikaʻi nui:
- Palekana Protease: ʻO ke kāohi ʻana i ka iwi kuamoʻo e hūnā i nā paʻa amide mai nā wahi hana enzyme, hoʻonui i ka hapalua o ke ola o ka serum mai nā minuke a i nā hola.
- Hoʻopiʻi Hui: ʻO ka laka conformational ka mea e pale ai i ka peptide mai ka hoʻohana ʻana i nā hale beta-sheet lōʻihi e alakaʻi ai i ka hui pilikino inter-chain i ka hopena..
Hoʻopaʻa ʻana i ka hydrocarbon (e.g., ʻO ka metathesis pani pani me ka hoʻohana ʻana i nā waikawa amino olefinic kūlohelohe) hoʻopaʻa i nā hale alpha-helical, ke alakaʻi nei i ke komo ʻana o ka intracellular a me ka huli ʻana i nā pilina protein-protein intracellular (PPI).
2. ʻOkoʻa Kemika Ma waho aʻe o ka 20 Nā ʻakika Amino kūlohelohe
E hoʻoponopono i ka solubility a me ka metabolic aie, ʻO nā papa hana synthesis maʻamau e hoʻokomo i nā poloka hale ʻaʻole canonical:
- N-Methylation: ʻO ka hoʻololi ʻana i nā hydrogen amide me nā hui methyl e hoʻopau i ka hoʻopaʻa ʻana i ka hydrogen inter-chain, ka hoʻomaikaʻi ʻana i ka solubility wai a me ka permeability membrane passive.
- D-Amino Acid & Nā kaulahao ʻaoʻao kūlohelohe: Hoʻololi i nā D-enantiomers a i ʻole nā ʻakika amino kūlohelohe ʻole (e.g., Hiki, Aib, ʻO Cha) poloka i ka ʻike enzymatic ʻoiai e mālama ana i nā wahi pili kaulahao ʻaoʻao.
- Lipidation a me PEGylation: ʻO ka hoʻohui ʻana i nā kaulahao momona C16/C18 e hoʻoikaika i ka hoʻopaʻa ʻana i ka albumin serum, pale i ka peptide mai ka hoʻomaʻemaʻe ʻana i ka renal a me ka hoʻonui nui ʻana i ka manawa kaʻa in-vivo.
Ke komo ʻana i kēia mau mea nā hoʻolālā hoʻololi peptide kūikawā hiki i nā hui ʻike ke hoʻopaʻa pono i nā hits i hana ʻia e AI no ka solubility, hikiwawe, a me ke kūpaʻa metabolic.
ʻIkepili Orthogonal: Ke hōʻoiaʻiʻo nei i ke ʻano o ke kaʻina, Maemae, a me Biocomparability
He koʻikoʻi ka pou kauoha hope o ka ʻōnaehana hybrid, hōʻailona analytical orthogonal. Pono e kākoʻo ʻia ka synthesis kiʻekiʻe e ka QC analytical uncompromised e hōʻoia i nā hopena bioassay e hōʻike i ke kaʻina pahuhopu maoli ma mua o nā mea hana synthetic a i ʻole nā mea haumia..
ʻO Peptide ʻAha Maka (SPSS)
Hoomaemae RP-HPLC (214 nm, Rs ≥ 1.5) Hōʻoia ʻo ESI-MS Monoisotopic Hōʻoia Kiʻekiʻe TFA Counterion Exchange (Acetate/Cloride) Papa 100 Hoʻomaʻemaʻe maʻemaʻe & Endotoxin QC
1. RP-HPLC a me ESI-MS
Pono e hana ʻia ka hoʻomaʻemaʻe me ka hoʻohana ʻana i ka Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) me ka ʻike UV ʻelua-lōʻihi, ka nānā pono 'ana i ka ho'opa'a peptide iwi kuamo'o ma 214 nm. ʻO ka hoʻonā Chromatographic ma waena o ka piko i hoʻopaʻa ʻia a me ka holoi ʻana i nā mea haumia pono e mālama iā R⛛ ≥ 1.5. Pono e hōʻoia ʻia ka ʻike kikoʻī ma o High-Resolution Electrospray Ionization Mass Spectrometry (ESI-MS), hoʻohālikelike i ka nui monoisotopic i loko o ± 0.02 A.
2. Hoʻololi Kūʻē TFA Systematic
No ka pale ʻana i nā mea hana hoʻāʻo cell, hana nā kaʻina hana synthesis maʻamau i ka hoʻololi paʻakai ʻōnaehana, ke hoʻololi nei i nā counterions TFA ʻawaʻawa me ka lāʻau inert acetate a i ʻole chloride ion. Pono e hōʻoia ʻia ka maikaʻi o ka hoʻololi ʻana ma o ka ion chromatography, e hōʻoia ana e hāʻule nā pae TFA koena ma lalo 1.0%.
3. Hoʻopaʻa maʻemaʻe a me Endotoxin
No ka moʻomeheu cell assays, ka nānā ʻana i nā organoid, a i ʻole ka hoʻāʻo in-vivo, ʻAʻole lawa ka maʻemaʻe wale nō. Mea hana i loko o ka Papa 100 ʻO nā wahi lumi hoʻomaʻemaʻe ultra-sterile e pale i ka hoʻohaumia ʻana i ka endotoxin bacteria. Pono ka ho'āʻo LAL Chromogenic Quantitative e hōʻoia i nā pae endotoxin ma lalo 0.01 EU/mg, ka pale ʻana i nā hōʻike biological mai ka hoʻoulu ʻana i ka immune-activation false positives.
Ma hope o kahi kūlana ʻO AI-designed peptide CDMO handoff protocol a me ke koi ʻana i nā CoA pūʻulu me nā chromatograms maka mai ka hoʻāʻo analytical ikaika a me nā protocol QC hōʻoia piha hoʻokolohua reproducibility.
Papa Hoʻomaʻamaʻa Hoʻomaʻamaʻa no nā hui noiʻi peptide kiʻekiʻe
Ma mua o ka hāʻawi ʻana i ke kapikala i ka nānā ʻana i ka wai-lab nui o nā hale waihona puke peptide i hana ʻia e AI., Pono nā alakaʻi noiʻi e hoʻopili i kēia papa helu 5-point physical de-risking checklist:
| Hōʻoia Triage | Kūlana Loiloi | Hana Hoʻoponopono inā ʻAʻole |
|---|---|---|
| 1. ʻO ka helu kūpono o ka SPPS | Pēta-pepa propensity < paepae; holo hydrophobic < 5 koena | Hoʻohui i ka pseudoproline dipeptides a i ʻole ka hoʻoheheʻe ʻana i ke kahe i kōkua ʻia i ka microwave |
| 2. Ka hoʻoheheʻe ʻana | Monomeric dissolution ma PBS buffer ma ≥ 100 µM me ke ao ʻole | Hoʻohui i ka PEGylation N-terminal, N-methylation, a i ʻole nā hōʻailona hydrophilic charged |
| 3. Serum Stability Benchmark | > 50% intact peptide i koe ma hope o 4-hola serum incubation | E hoʻolauna i ka cyclization poʻo a i ka huelo, D-amino acid pani, a i ʻole ka stapling |
| 4. Kūlana Kūʻē | ʻO ka acetate a i ʻole ka paʻakai chloride i hōʻoia ʻia me ke koena TFA < 1.0% | E hoʻomākaukau i ka hoʻololi kūʻē TFA ma mua o ka bioassays |
| 5. Palapala QC | RP-HPLC i hoʻopaʻa ʻole ʻia (214 nm) a me ke kiʻekiʻe kiʻekiʻe ESI-MS batch spectrum | E kauoha i ka hōʻoia CoA kikoʻī pūʻulu ma mua o ka hoʻomaka ʻana o ka hoʻāʻo |
No ke kōkua: Mai loiloi i ka maʻemaʻe peptide ma 254 nm a i ole 280 nm wale no. Nui nā peptides i nele i nā koena ʻala (Trp, ʻO Tyr, Ua haʻi aku ʻo Phe) a e ikeia ma ke ano maemae ma 280 nm oiai e huna ana i na haumia holoi nui i ikeia ma 214 nm.
Mākaʻikaʻi Kūlana & Nā Hōʻike i nānā ʻia e nā hoa
Hoʻopili kēia ʻano loiloi ʻenehana i nā hiʻohiʻona empirical synthesis me nā ʻikepili hoʻokolohua hoʻokolohua lehulehu a me nā palapala i loiloi ʻia e nā hoa i ka lāʻau lapaʻau., me nā alakaʻi FDA e pili ana i ka maʻemaʻe peptide synthetic a me ka mana maikaʻi (Ke alakaʻi FDA no ka ʻoihana: Nā ANDA no nā Huahana Laʻau Peptide Synthetic), noiʻi i paʻi ʻia ma Nature Chemistry, a me nā kūlana synthesis peptide ACS. ʻO nā kikoʻī analytical āpau (RP-HPLC Rs ≥ 1.5, ESI-MS ± 0.02 A, LAL < 0.01 EU/mg) hōʻike i nā kūlana biopharma i hoʻokumu ʻia no ka preclinical lead optimization.
Hōʻuluʻulu manaʻo & Nā ʻanuʻu aʻe
ʻO ka $8.9 billion invested in AI drug discovery has proven that computational algorithms are remarkable ideation engines. Eia naʻe, until algorithms can synthesize physical matter and navigate biological fluids, lead validation will remain grounded in wet-lab peptide chemistry.
By triaging AI-generated sequences through high-throughput bespoke synthesis, targeted chemical modifications (cyclization, nā ʻakika amino kūlohelohe, lipidation), and orthogonal analytical characterization, research teams can turn in-silico predictions into clinical leads.
To discuss de-risking your AI-designed peptide sequences, exploring custom modification strategies, or requesting batch-specific analytical QC, makaikai MOL Changes custom peptide synthesis solutions or consult directly with our technical chemistry team.
